Tagged with Regulation

investment Newcomers to Algeria’s fledgling, but increasingly vibrant pharmaceuticals sector are immediately struck by the sense of liveliness pervading the industry. Indeed, as growth patterns in developed markets continue to flatten, and the protagonists of ‘big pharma’ pivot towards securing new revenue sources in emergent economies, Algeria must surely constitute one…

distribution The Argentinian healthcare system is subject to rules, in which delivery agreements for medicines to health insurance agents undergo health funders guidelines and other regulations imposed by the Superintendency of Health Services Office. Dr. Raúl Pistorio, Executive Director of Farmalink, the company responsible for this process, discusses this peculiar regulatory arrangement.…

regulation Carlos Chiale, National Administrator of ANMAT, discusses the agency’s latest strategy implementation and its pioneering work in the area of fighting drug falsification.   Could you provide a historical overview of ANMAT, its main achievements and current activities today? Since its creation in 1992, ANMAT has performed activities intended for…

doctors MMA’s president shares the reasons why Malaysia is ranked today third in terms of healthcare quality, with a very efficient public system, high quality doctors and strong government support. However, the situation could change as too many doctors change to the private sector, NCDs are drastically increasing and financing healthcare…

IMS IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also shares the opportunities present for pharma companies to invest in Malaysia.     IMS is now providing data for the…

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…

regulation “We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says the President of PhAMA.    With the introduction of healthcare as one of the 12 National Key Economic Areas (NKEA)…

cost containment “Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has brought both benefits and shortcomings. One consequence is that Poland has the lowest average price of medicine in the European…

regulation PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high income nation by 2020 and a reference in terms of healthcare quality worldwide.   How would you describe the healthcare…

GMP Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with over 200 manufacturers. Can you please start by introducing your organization, Main Pharmaceutical Inspectorate, and explain how it fits within…

law “The advantage of working in a law firm such as SRS Advogados is that it favors specialization in specific legal areas, such as life sciences, in order to meet the client’s needs. The regulatory aspects require study and preparation and are the main aspects of the legal advice of the…

Infarmed Eurico Castro Alves, president of Portugal’s regulatory agency Infarmed, talks about the biggest challenges facing the regulation of health products in the country today, and introduces new initiatives aimed at positioning Infarmed as a regulator of reference worldwide.   You have been president of Infarmed since 2012. What have been some…